Exhaled breath analysis (EBA) has evolved as a noninvasive diagnostic technique with enormous promise in healthcare. The development in this area is based on the concept that the breathalyzers employed to measure the alcohol concentration in the blood can be utilized to evaluate health by analyzing the intricate chemical makeup of exhaled breath, which includes various volatile organic compounds (VOCs). Breath analysis could be the driver of personalized medicine and used in early disease identification as it involves the detection of a variety of disease‐specific biomarkers. In diagnostics, EBA offers a noninvasive procedure of illness identification and monitoring. This approach allows for early detection, personalized treatment options, and therapeutic monitoring by detecting disease‐specific VOC biomarkers such as acetone in diabetes and ethane in lipid peroxidation. Also, EBA can measure environmental exposures such as air pollution or occupational dangers. By identifying VOCs from various sources, researchers can measure exposure levels and assess related health hazards. Advances in the analytical methods, including mass spectrometry, gas chromatography, and sensor arrays made it possible to quantify and identify VOCs in exhaled air with high sensitivity and precision. This review focuses on the biomarkers present in breath and their role in identifying diseases. It covers the essential compounds found in breath and their biochemical processes. Furthermore, an in‐depth examination of different methods for identifying biomarkers in breath and the factors influencing VOC concentrations, including age, storage conditions, external sources, and the difference between dead space air and alveolar air, has been discussed.
Parikh et al. (Thu,) studied this question.